Clinical trials recruiting in Barrie, Canada

Phase breakdown

Conditions recruiting in Barrie, Canada

Recruiting trials in Barrie, Canada

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
  NCT05417516 · Phase: Phase 3 · Ages: 50 Years to 120 Years · Sex: Female
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
  NCT06792695 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
  NCT07219420 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
  NCT06235697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
  NCT06877598 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
  NCT07474792 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female)
• Duration of Anti-PD-1 Therapy in Metastatic Melanoma
  NCT02821013 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Modifying PEST for Psoriatic Arthritis Screening
  NCT06382051 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
  NCT05592938 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: Female
• Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
  NCT04797299 · Phase: Not specified · Ages: 46 Years and older · Sex: Female
• Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
  NCT05866458 · Phase: Not specified · Ages: 50 Years and older · Sex: Female
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
  NCT07245394 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Barrie, Canada?

33 recruiting trials have at least one study site in Barrie, Canada.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.